Research Summaries

Antimicrobial peptides (AMPs) are emerging as promising alternatives to conventional antibiotics in the fight against drug-resistant infections. These naturally occurring molecules employ multiple mechanisms including membrane disruption, intracellular targeting, and immunomodulation, making bacterial resistance development slower and more costly than with traditional antibiotics.

Preclinical rat studies demonstrate that BPC-157, a gastric pentadecapeptide, accelerates Achilles tendon and medial collateral ligament healing through growth hormone receptor upregulation and angiogenesis modulation. The peptide shows efficacy via oral, injectable, and topical administration routes.

Multiple systematic reviews and meta-analyses of randomized controlled trials demonstrate that oral collagen peptide supplementation significantly improves skin hydration and elasticity, reduces joint pain, and increases bone mineral density. The evidence is strongest for skin outcomes across 26 pooled RCTs.

Broad Institute Connectivity Map analysis reveals that GHK-Cu modulates approximately 4,000 human genes, including 47 DNA repair genes and key extracellular matrix regulators. Preclinical studies across multiple animal models demonstrate accelerated wound healing, enhanced collagen synthesis, and anti-inflammatory tissue remodeling.

Multiple randomized, placebo-controlled clinical trials demonstrate that oral NMN supplementation safely and dose-dependently elevates blood NAD+ levels in humans. Higher doses (600-900 mg/day) showed statistically significant improvements in physical performance and quality of life measures, suggesting NMN as a promising strategy for addressing age-related NAD+ decline.

Personalized neoantigen peptide vaccines have demonstrated safety and immunogenicity in early clinical trials across melanoma, hepatocellular carcinoma, and NSCLC. Combination with PD-1 checkpoint inhibitors appears to enhance anti-tumor responses, with landmark melanoma data showing 67% recurrence-free survival at 25 months.

The SELECT trial demonstrated that semaglutide reduces major adverse cardiovascular events by 20% in patients with obesity and established heart disease, independent of diabetes. A separate phase 2 trial showed semaglutide resolves non-alcoholic steatohepatitis (NASH) in a significant proportion of patients, while emerging evidence points to neuroprotective potential through GLP-1 receptor pathways.

Semax, a synthetic ACTH(4-10) analogue, rapidly upregulates BDNF protein levels in the basal forebrain and demonstrates neuroprotective effects in both preclinical ischemia models and clinical stroke studies. The peptide accelerates neurological recovery and shows cognitive enhancement properties mediated through neurotrophic signaling.

Thymosin Beta-4 activates integrin-linked kinase and Akt survival signaling to protect cardiomyocytes after myocardial infarction, as demonstrated in landmark preclinical studies. A first-in-human phase I trial has confirmed safety and tolerability, paving the way for efficacy studies in acute MI patients.

The SURPASS clinical trial program demonstrated that tirzepatide, a dual GIP/GLP-1 receptor agonist, delivers HbA1c reductions of up to 2.6% and body weight loss of up to 13.9% in type 2 diabetes. Head-to-head data from SURPASS-2 showed superiority over semaglutide for both glycemic control and weight loss.